Main Business - The company's main products include safety infusion devices and blood purification equipment, with significant revenue declines in safety infusion single machines and blood purification single machines, down 39.59% and 100.00% respectively, while blood purification continuous machines saw substantial growth [2][5][6] - The first major customer accounted for a significant portion of annual sales, with the increase in transaction amount attributed to the growth in the blood purification product business and the overall industry [2][14] Supplier Information - The company sources all standard parts externally, with a mix of self-manufactured, custom procurement, and outsourced processing for non-standard components. The total procurement amount for 2024 was 23,959.42 million yuan, a decrease of 36.99% compared to the previous year [28][29] Inventory and Contract Liabilities - The company reported that the inventory of blood purification single machines remained unsold due to production cycle delays and customer facility issues, impacting revenue recognition [11][12] - The company maintains a production model based on order fulfillment, which has led to fluctuations in sales revenue for blood purification single machines [11][12] Accounts Receivable and Long-term Receivables - The company provided details on its top five customers, including transaction amounts and payment conditions, indicating a healthy receivables situation with good recovery rates [13][15] Goodwill Impairment - There were no indications of impairment for the company's assets, as the net realizable value of blood purification single machines exceeded their costs, negating the need for inventory write-downs [12][25] Construction in Progress - The company has invested in the development of its contact lens manufacturing subsidiary, with a focus on material research and production line construction, indicating a strategic expansion into the optical sector [3][24] Market Trends - The blood dialysis medical device market in China is projected to grow steadily, with a compound annual growth rate of 5.67% from 2019 to 2023, expected to reach 51.515 billion yuan by 2030 [6][14] - The company is also expanding into the contact lens market, which is anticipated to grow significantly, with the transparent and colored contact lens markets projected to reach 161 billion yuan and 183 billion yuan respectively by 2030 [18][20]

Company Overview - Maide Medical's stock closed at 14.61 yuan, up 1.67%, with a latest price-to-book ratio of 3.09, marking a new low in 231 days, and a total market capitalization of 2.428 billion yuan [1] - As of the first quarter of 2025, five institutions held shares in Maide Medical, including three funds, one other entity, and one social security fund, with a total holding of 15.2835 million shares valued at 179 million yuan [1] - The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with main products including safety infusion and blood purification devices [1] Performance Metrics - For the first quarter of 2025, Maide Medical reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87%, and a net profit of -10,797,370.24 yuan, a year-on-year decline of 202.70%, with a gross profit margin of 32.89% [1] - The company's price-to-earnings ratio (TTM) is -58.81, and the static PE is -121.54, with a market capitalization of 2.428 billion yuan [2] - The industry average PE (TTM) is 60.04, and the industry median is 49.67, indicating that Maide Medical's valuation metrics are significantly lower than the industry averages [2]

Core Viewpoint - MaiDe Medical's stock closed at 14.03 yuan, up 3.47%, with a latest price-to-book ratio of 2.97, marking a new low in 156 days, and a total market capitalization of 2.332 billion yuan [1] Group 1: Company Overview - MaiDe Medical Industrial Equipment Co., Ltd. specializes in the research, development, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main products include safety infusion and blood purification equipment [1] - The company has been recognized with qualifications such as the establishment of a postdoctoral workstation in Zhejiang Province and participation in various provincial projects [1] Group 2: Financial Performance - As of the first quarter of 2025, the company reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87% [1] - The net profit for the same period was -10,797,370.24 yuan, reflecting a year-on-year decline of 202.70% [1] - The sales gross margin stood at 32.89% [1] Group 3: Institutional Holdings - As of the first quarter of 2025, five institutions held shares in MaiDe Medical, including three funds, one other institution, and one social security fund, with a total holding of 15.2835 million shares valued at 17.9 million yuan [1]

4月16日，迈得医疗今日收盘10.71元，下跌2.46%，最新市净率2.12，总市值17.80亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入2.20亿元，同比-33.45%；净利润762.99万元，同 比-89.37%，销售毛利率48.86%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)18迈得医疗-90.14-90.142.1217.80亿行业平均 59.8664.934.0355.86亿行业中值44.0041.162.7035.18亿1巨能股份-1833.67-1833.677.8320.52亿2亿嘉 和-1775.95-667.952.9267.17亿3巨轮智能-1677.13-648.428.16198.39亿4远大智能-760.54113.033.0335.06亿 5开勒股份-501.98131.824.3935.40亿6蓝英装备-373.89-338.107.7170.94亿7大宏立-320.72- 1743.082.3119.82亿8永创智能-259.4461.221.8043.50亿9爱司凯-217.24-484.316.0029.23亿10上工申 贝-187.398 ...